Neurocrine Biosciences (NBIX) Misses Q4 EPS by 54c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $177.49 --0%
Revenue Growth %: +27.0%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
CRMT, PKE, HELE, More
Revenue Growth %: +27.0%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.04, $0.54 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $303.5 million versus the consensus estimate of $320 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
- Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
- Abitibi Metals names new CFO, halts drilling on Quebec fire order
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
